Biond Biologics is an Israeli biopharmaceutical company developing innovative immunotherapies and a pioneering intracellular drug delivery platform for the treatment of cancer patients.
The company announced that its innovative BND-35 immunotherapy began its first human clinical trial at the Rabin Medical Center Oncology Institute, Davidoff Center.
BND-35 is an antagonist antibody developed for the treatment of solid tumors. So far, in vitro and ex vivo studies have shown that BND-35 enhances the proinflammatory activity of various myeloid cells and inhibits the immunosuppressive activity of suppressive myeloid cells.
Salomon Stemmer, head of Research, Development and Innovation and deputy director of the Davidoff Center explained that “the BND-35 trial design introduces a novel combination therapy that targets the immunosuppressive cellular environment within the tumor microenvironment.”